Joly Etienne, Maurel Ribes Agnès
CNRS, Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, Toulouse 31000, France.
Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, 31000 Toulouse, France.
Biol Methods Protoc. 2022 Nov 28;7(1):bpac026. doi: 10.1093/biomethods/bpac026. eCollection 2022.
The haemagglutination test (HAT)-field protocol described here is an optimization of the recently published HAT, for the detection of antibodies directed against the receptor binding domain (RBD) of the SARS-Cov-2 virus. HAT and HAT-field are both based on haemagglutination triggered by a single reagent, the IH4-RBD recombinant protein. A sample of IH4-RBD sufficient for several thousand tests or a plasmid encoding IH4-RBD can be obtained from the authors of our first paper. Using titration of IH4-RBD, HAT-field now allows a quantitative assessment of antibody levels in a single step, using a few microliters of whole blood, such as can be obtained by finger prick, and requires only very simple disposable equipment. Because it is based on a single soluble reagent, the test can be adapted very simply and rapidly to detect antibodies against variants of the SARS-CoV-2, or conceivably against different pathogens. HAT-field appears well suited to provide quantitative assessments of the serological protection of populations as well as individuals, and given its very low cost, the stability of the IH4-RBD reagent in the adapted buffer and the simplicity of the procedure, could be deployed pretty much anywhere, including in the poorest countries and the most remote corners of the globe.
本文所述的血凝试验(HAT)现场检测方案是对最近发表的HAT的优化,用于检测针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒受体结合域(RBD)的抗体。HAT和HAT现场检测均基于由单一试剂IH4-RBD重组蛋白引发的血凝反应。可从我们第一篇论文的作者处获得足以进行数千次检测的IH4-RBD样本或编码IH4-RBD的质粒。通过对IH4-RBD进行滴定,HAT现场检测现在可以使用几滴全血(如通过手指针刺采集)在一步中对抗体水平进行定量评估,并且仅需要非常简单的一次性设备。由于它基于单一可溶性试剂,该检测可以非常简单和快速地进行调整,以检测针对SARS-CoV-2变体或可能针对不同病原体的抗体。HAT现场检测似乎非常适合对人群以及个体的血清学保护进行定量评估,并且鉴于其成本非常低、IH4-RBD试剂在适配缓冲液中的稳定性以及操作的简单性,几乎可以在任何地方使用,包括在最贫穷的国家和全球最偏远的角落。